SEC Company Response from Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425) (MIRM) — Jan 6, 2020
Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)
Date: Jan. 6, 2020 · CIK: 0001759425 · Accession: 0001193125-20-002352
AI Filing Summary & Sentiment
File numbers found in text: 333-235825
Letter
Re: Mirum Pharmaceuticals, Inc.
January 6, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (File No. 333-235825)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Mirum Pharmaceuticals, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 P.M., Eastern Time, on January 8, 2020, or as soon thereafter as practicable, or at such other time thereafter as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as the representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
CITIGROUP GLOBAL MARKETS INC. EVERCORE GROUP L.L.C.
Show Raw Text
CORRESP 1 filename1.htm CORRESP January 6, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Mirum Pharmaceuticals, Inc. Registration Statement on Form S-1 (File No. 333-235825) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Mirum Pharmaceuticals, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 P.M., Eastern Time, on January 8, 2020, or as soon thereafter as practicable, or at such other time thereafter as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as the representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Signature page follows] Very truly yours, CITIGROUP GLOBAL MARKETS INC. EVERCORE GROUP L.L.C. As representatives of the several underwriters listed in Schedule I to the Underwriting Agreement CITIGROUP GLOBAL MARKETS INC. By: /s/ Bradley Wolff Name: Bradley Wolff Title: Managing Director EVERCORE GROUP L.L.C. By: /s/ Gloria Tang Name: Gloria Tang Title: Vice President [Signature Page to Underwriters’ Acceleration Request]